Chinese specialty pharmaceutical firm Eddingpharm has received an exclusive, royalty-bearing license from Ablynx to develop and commercialize its anti-RANKL Nanobody, ALX-0141, in China, the Hong Kong and Macao Special Administrative ...
Tags: Eddingpharm, Anti-Rankl Nanobody
Ablynx has commenced pre-clinical development of ALX-0962, an anti- immunoglobulin E (IgE) nanobody, to treat severe allergic asthma and expects to begin Phase I development in the second half of 2014. ALX-0962 comprises anti-IgE Nanobody ...
Tags: Ablynx, Pre-Clinical Development
Ablynx has signed a collaborative agreement with Spirogen to evaluate the potential of a novel anti-cancer drug conjugate. As part of the deal, both the firms will evaluate anti-cancer drug conjugate by using Spirogen's proprietary ...
Tags: Ablynx inks, anti cancer drug, drug
Merck and Ablynx have entered into a partnership to develop Nanobody candidates against a voltage gated ion channel and includes an option to elect a second target. As a part of the agreement, Ablynx will be responsible for the discovery ...
Tags: Nanobody Candidates, Nanobody technology, Ablynx Partner